a lady holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a clinical syringe during this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File picture
TOKYO, Sept 7 (Reuters) - Japan has selected three candidates for COVID-19 remedies to acquire subsidies for clinical trials, the fitness ministry observed on Tuesday.
The medicine are AstraZeneca Plc's (AZN.L) antibody medicine AZD7442, Shionogi & Co's (4507.T) protease inhibitor S-217622, and Fujifilm conserving Corp's (4901.T ) antiviral favipiravir, universal commercially as Avigan.
Reporting via Rocky Swift; enhancing by using Clarence Fernandez
Our specifications: The Thomson Reuters trust ideas.
0 Comments